Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Bioinspired virus-like nanovaccines boost CAR T and endogenous T cells in tandem against solid tumors with antigen heterogeneity

Award Number: R01CA300077
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 05/13/2026
PERIOD OF PERFORMANCE END DATE: 04/30/2031

Group Awards By:

View Award Description

Bioinspired virus-like nanovaccines boost CAR T and endogenous T cells in tandem against solid tumors with antigen heterogeneity - Project Summary/Abstract Adoptive cell therapy with chimeric antigen receptor (CAR) T cells targeting a single tumor-specific surface antigen has demonstrated remarkable long-term efficacy in certain hematological malignancies. This success led to its approval by the FDA for the treatment of multiple hematological cancers. However, the clinical outcomes of CAR T therapy in solid tumors have been largely disappointing. A key obstacle is the pre-existing antigen heterogeneity in solid tumors, which often results in antigen-negative tumor escape, because not all tumor cells express the antigen targeted by the CAR. Pre-clinical and clinical studies have shown that polyclonal T-cell responses against different tumor antigens, or even the same antigen, could lead to superior tumor control in the long term. We recently published that vaccine boosting of CAR T cells stimulated CAR T cell expansion with enhanced functionality and unexpectedly triggered antigen spreading, resulting in more effective treatment of tumors with antigen heterogeneity in an animal model. More specifically, this was achieved by using a lymph- node targeting lipid polymer to deliver the natural ligand recognized by the CAR to antigen-presenting cells (APCs). However, the kinetics and magnitude of antigen spreading may not be sufficient for treating tumors with a high proportion of tumor cells missing the CAR antigen. Building on these findings, we will develop an autologous tumor cell membrane-coated dual CAR and endogenous T cell boosting virus-like nanoparticle vaccine (dtVLP-vax) to overcome this barrier. The dtVLP-vax particles retain on their surfaces a collection of tumor-associated antigens (TAAs), including the antigen recognized by the CAR and peptide-major histocompatibility complexes (pMHCs) recognized by T cell receptors (TCRs). These antigens will be transferred onto the APCs upon arrival in the LN, allowing natural APCs to boost both adoptively transferred tumor-targeting CAR T cells and endogenous tumor-specific T cells, generating a polyclonal anti-tumor T cell response. The unbiased presentation of all TAAs, especially pMHCs, by dtVLP-vax also eliminates the need for tumor sequencing and neoantigen identification, which is often costly and time-consuming. We hypothesize that dtVLP-vax can efficiently support CAR T therapy and amplify endogenous T cells to rapidly diversify and broaden the anti-tumor T cell immunity, thereby facilitating a more effective control of solid tumors with antigen heterogeneity. Using multiple solid tumor models, we aim to (1) Characterize the biology and mechanisms of dtVLP-vax for stimulating CAR T and endogenous T cells in vivo. (2) Assess the versatility of the dtVLP-vax platform for reprogramming T cells. (3) Evaluate the capacity of dtVLP-vax to boost both CAR T cells and endogenous T cells with enhanced diversity and functionality against solid tumors displaying antigen heterogeneity. (4) Assess the human tumor-derived dtVLP-vax. These studies will establish key principles of dtVLP-vax designs to maximize the potential of adoptive cell therapy for solid tumors.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $737,082 )
2026	2026	THE CHILDREN'S HOSPITAL OF PHILADELPHIA	3401 CIVIC CENTER BLVD	PHILADELPHIA	PA	19104	PHILADELPHIA	USA	Cancer Treatment Research	000	1	5/19/2026	NEW	$737,082
														Subtotal = $737,082

Grand Total All Awards = $737,082

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Bioinspired virus-like nanovaccines boost CAR T and endogenous T cells in tandem against solid tumors with antigen heterogeneity

Award Number: R01CA300077

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 05/13/2026

PERIOD OF PERFORMANCE END DATE: 04/30/2031

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer